211 related articles for article (PubMed ID: 29776391)
1. The clinical implications of G1-G6 transcriptomic signature and 5-gene score in Korean patients with hepatocellular carcinoma.
Ahn SM; Haq F; Park I; Nault JC; Zucman-Rossi J; Yu E
BMC Cancer; 2018 May; 18(1):571. PubMed ID: 29776391
[TBL] [Abstract][Full Text] [Related]
2. The transcriptomic G1-G6 signature of hepatocellular carcinoma in an Asian population: Association of G3 with microvascular invasion.
Allen JC; Nault JC; Zhu G; Khor AYK; Liu J; Lim TKH; Zucman-Rossi J; Chow PKH
Medicine (Baltimore); 2016 Nov; 95(47):e5263. PubMed ID: 27893662
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of transcriptomic molecular classification, biological behavior, and clinicopathological features in hepatocellular carcinoma.
Chen R; Zhou Z; Chen Y; Huang A; Chen L
Expert Rev Mol Diagn; 2023 Jan; 23(1):71-84. PubMed ID: 36655856
[TBL] [Abstract][Full Text] [Related]
4. Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification.
Calderaro J; Couchy G; Imbeaud S; Amaddeo G; Letouzé E; Blanc JF; Laurent C; Hajji Y; Azoulay D; Bioulac-Sage P; Nault JC; Zucman-Rossi J
J Hepatol; 2017 Oct; 67(4):727-738. PubMed ID: 28532995
[TBL] [Abstract][Full Text] [Related]
5. Clinical Impact of Genomic Diversity From Early to Advanced Hepatocellular Carcinoma.
Nault JC; Martin Y; Caruso S; Hirsch TZ; Bayard Q; Calderaro J; Charpy C; Copie-Bergman C; Ziol M; Bioulac-Sage P; Couchy G; Blanc JF; Nahon P; Amaddeo G; Ganne-Carrie N; Morcrette G; Chiche L; Duvoux C; Faivre S; Laurent A; Imbeaud S; Rebouissou S; Llovet JM; Seror O; Letouzé E; Zucman-Rossi J
Hepatology; 2020 Jan; 71(1):164-182. PubMed ID: 31206197
[TBL] [Abstract][Full Text] [Related]
6. Upregulation of Stress-Induced Protein Kinase CK1 Delta is associated with a Poor Prognosis for patients with Hepatocellular Carcinoma.
Zhang H; Qiu C; Zeng H; Zhu W; Lyu W; Lao X
Genet Test Mol Biomarkers; 2021 Jul; 25(7):504-514. PubMed ID: 34280005
[No Abstract] [Full Text] [Related]
7. Six-long non-coding RNA signature predicts recurrence-free survival in hepatocellular carcinoma.
Gu JX; Zhang X; Miao RC; Xiang XH; Fu YN; Zhang JY; Liu C; Qu K
World J Gastroenterol; 2019 Jan; 25(2):220-232. PubMed ID: 30670911
[TBL] [Abstract][Full Text] [Related]
8. Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets.
Boyault S; Rickman DS; de Reyniès A; Balabaud C; Rebouissou S; Jeannot E; Hérault A; Saric J; Belghiti J; Franco D; Bioulac-Sage P; Laurent-Puig P; Zucman-Rossi J
Hepatology; 2007 Jan; 45(1):42-52. PubMed ID: 17187432
[TBL] [Abstract][Full Text] [Related]
9. Identification of a five-long non-coding RNA signature to improve the prognosis prediction for patients with hepatocellular carcinoma.
Zhao QJ; Zhang J; Xu L; Liu FF
World J Gastroenterol; 2018 Aug; 24(30):3426-3439. PubMed ID: 30122881
[TBL] [Abstract][Full Text] [Related]
10. Construction and Validation of a Prognostic Gene-Based Model for Overall Survival Prediction in Hepatocellular Carcinoma Using an Integrated Statistical and Bioinformatic Approach.
Dessie EY; Tu SJ; Chiang HS; Tsai JJP; Chang YS; Chang JG; Ng KL
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33562824
[TBL] [Abstract][Full Text] [Related]
11. A gene-based risk score model for predicting recurrence-free survival in patients with hepatocellular carcinoma.
Wang W; Wang L; Xie X; Yan Y; Li Y; Lu Q
BMC Cancer; 2021 Jan; 21(1):6. PubMed ID: 33402113
[TBL] [Abstract][Full Text] [Related]
12. Identification and validation of a potent multi-mRNA signature for the prediction of early relapse in hepatocellular carcinoma.
Cai J; Tong Y; Huang L; Xia L; Guo H; Wu H; Kong X; Xia Q
Carcinogenesis; 2019 Jul; 40(7):840-852. PubMed ID: 31059567
[TBL] [Abstract][Full Text] [Related]
13. Identification and validation of redox-immune based prognostic signature for hepatocellular carcinoma.
Tu K; Li J; Mo H; Xian Y; Xu Q; Xiao X
Int J Med Sci; 2021; 18(9):2030-2041. PubMed ID: 33850474
[TBL] [Abstract][Full Text] [Related]
14. Overexpressed GNAZ predicts poor outcome and promotes G0/G1 cell cycle progression in hepatocellular carcinoma.
Tian F; Cai D
Gene; 2022 Jan; 807():145964. PubMed ID: 34530087
[TBL] [Abstract][Full Text] [Related]
15. Construction and validation of a three-microRNA signature as prognostic biomarker in patients with hepatocellular carcinoma.
Zhang X; Ma L; Zhai L; Chen D; Li Y; Shang Z; Zhang Z; Gao Y; Yang W; Li Y; Pan Y
Int J Med Sci; 2021; 18(4):984-999. PubMed ID: 33456356
[TBL] [Abstract][Full Text] [Related]
16. Upregulation of FEN1 Is Associated with the Tumor Progression and Prognosis of Hepatocellular Carcinoma.
Zhang Y; Liu X; Liu L; Chen J; Hu Q; Shen S; Zhou Y; Chen S; Xue C; Cui G; Yu Z
Dis Markers; 2020; 2020():2514090. PubMed ID: 32399086
[TBL] [Abstract][Full Text] [Related]
17. Identification and characterization of a 25-lncRNA prognostic signature for early recurrence in hepatocellular carcinoma.
Fu Y; Wei X; Han Q; Le J; Ma Y; Lin X; Xu Y; Liu N; Wang X; Kong X; Gu J; Tong Y; Wu H
BMC Cancer; 2021 Oct; 21(1):1165. PubMed ID: 34717566
[TBL] [Abstract][Full Text] [Related]
18. Integrative analysis of DNA methylation and gene expression reveals distinct hepatocellular carcinoma subtypes with therapeutic implications.
Huang X; Yang C; Wang J; Sun T; Xiong H
Aging (Albany NY); 2020 Mar; 12(6):4970-4995. PubMed ID: 32201399
[TBL] [Abstract][Full Text] [Related]
19. Genomic analysis of liver cancer unveils novel driver genes and distinct prognostic features.
Li X; Xu W; Kang W; Wong SH; Wang M; Zhou Y; Fang X; Zhang X; Yang H; Wong CH; To KF; Chan SL; Chan MTV; Sung JJY; Wu WKK; Yu J
Theranostics; 2018; 8(6):1740-1751. PubMed ID: 29556353
[No Abstract] [Full Text] [Related]
20. Identification of survival-related predictors in hepatocellular carcinoma through integrated genomic, transcriptomic, and proteomic analyses.
Dong F; Yang Q; Wu Z; Hu X; Shi D; Feng M; Li J; Zhu L; Jiang S; Bao Z
Biomed Pharmacother; 2019 Jun; 114():108856. PubMed ID: 30981109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
